# Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

> **NCT06500819** · PHASE1 · RECRUITING · sponsor: **Stanford University** · enrollment: 41 (estimated)

## Conditions studied

- Neuroblastoma
- Sarcoma
- Osteosarcoma

## Interventions

- **DRUG:** B7-H3CART Dose (Intravenous)

## Key facts

- **NCT ID:** NCT06500819
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500819, "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT06500819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*